Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older

Selpercatinib is in clinical development for the treatment of advanced solid tumours with a mutation in the gene known as RET, which is involved in cell signalling or cell communication. Solid tumours are abnormal masses of tissue that usually do not contain cysts or liquid areas. A cancer cell’s RET gene can move or fuse to another gene, which is referred to as RET gene fusions. When this occurs, cancer cells can spread and grow rapidly. RET fusions in people with solid tumours are associated with more aggressive forms of diseases and poorer outcomes for patients. Inhibiting RET in cancer tumours has shown to slow the growth of cancer cells and improve patient outcomes.